India’s 1st COVID-19 Vaccine - COVAXIN™, Developed by Bharat Biotech gets DCGI approval for Phase I & II Human Clinical Trials

Bharat Biotech has successfully developed COVAXIN™, India’s 1st vaccine candidate for COVID-19, in

collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The

indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety

Level 3) High Containment facility located in Genome Valley, Hyderabad, India.

https://www.bharatbiotech.com/images/press/Indias-1st-COVID-19-Vaccine-COVAXIN-Developed-by-Bharat-Biotech-gets-DCGI-approval-for-Phase-I-and-II-Human-Clinical-Trials.pdf